○Optimizing treatment with tumour necrosis factor inhibitors in
rheumatoid arthritis‒a proof of principle and exploratory trial:is
dose tapering practical in good responders?
○Safety, tolerability, and pharmacodynamics of ABT‒122, a tumor
necrosis factor‒ and interleukin‒17‒targeted dual variable
domain immunoglobulin, in patients with rheumatoid arthritis.
○Identification of definitive serum biomarkers associated with
disease activity in primary Sjögren’s syndrome.
○Disruption of CXCR3 function impedes the development of
Sjögren's syndrome‒like xerostomia in non‒obese diabetic mice.
○Neuropsychiatric lupus or not? Cerebral hypoperfusion by
perfusion‒weighted MRI in normal‒appearing white matter in primary
neuropsychiatric lupus erythematosus.
○Metabolic and cardiovascular benefits of hydroxychloroquine in
patients with rheumatoid arthritis:a systematic review and